Combining JAB-21822 and JAB-3312 for advanced lung cancer with KRAS mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 study evaluates the effectiveness of a combination of JAB-21822 and JAB-3312 compared to standard treatment with tislelizumab, pemetrexed, and carboplatin for patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS p.G12C mutation. The trial aims to determine if this new combination can provide better outcomes than the current standard of care. Participants will be monitored for their response to treatment and any side effects experienced during the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A signed written informed consent is required before performing any study-related operations
* Age greater than or equal to 18 years old
* Histologically or cytologically confirmed locally advanced/metastatic, unresectable non-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab
* No history of systemic anticancer therapy to the local advanced/metastatic disease
* Expected survival period greater than or equal to 3 months
* Having at least one target lesion according to RECIST 1.1
* Eastern Cooperative Oncology Group (ECOG) ≤ 1

Exclusion Criteria:

* Previous (≤2 years) or current solid tumors or hematologic tumors of other pathological types
* Carry other driver gene mutations with available target therapy, or carry other KRAS mutations
* Subjects with untreated central nervous system (CNS) metastases were excluded;
* Uncontrolled pleural effusion, pericardial effusion, and ascites
* Subjects with impaired heart function or clinically significant heart disease

Where it's running

• Cancer Hospital Chinese Academy Of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting
• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Chest Hospital ,Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• Cangzhou hospital of integrated TCM-WM Hebei
  Cangzhou, Hebei, China Recruiting
• Shandong Cancer Hospital
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Wang Jie M.D. — Cancer Institute and Hospital
• Study coordinator: Shanghai Allist Pharmaceuticals Co., Ltd
• Email: zhenhua.gong@allist.com.cn
• Phone: 021-80423288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New treatment for advanced non-small-cell lung cancer using a virus and chemotherapy

  This study is testing a new treatment that combines a special virus and chemotherapy to see if it can help people with advanced lung cancer who haven't responded to previous treatments.

  Recruiting at 15 sites Phase 2 Genelux Corporation · Bullhead City, Arizona and 14 other locations · NCT06463665

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Tislelizumab plus Anlotinib after chemoradiotherapy in limited-stage SCLC

  This phase II trial tests whether adding tislelizumab and anlotinib after chemoradiotherapy helps people with limited-stage small cell lung cancer stay cancer-free.

  Recruiting Phase 2 Yantai Yuhuangding Hospital · Yantai, Shandong · NCT07815223

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.